A glioblastoma diagnosis moves fast. Within days of surgery you may be asked to agree to a treatment plan. Before you do, you should know what a real second opinion includes. A genuine expert review goes much deeper than having another doctor confirm what the first doctor found.
This article explains the seven components of a complete glioblastoma second opinion, what records and tests you need for each one, and a checklist to help you gather everything before you contact a specialist center.
What does a comprehensive glioblastoma second opinion include?
A complete glioblastoma second opinion includes independent review of your pathology slides, molecular marker testing (MGMT, IDH, TERT, EGFR, CDKN2A), neuroradiology re-read of all MRI sequences, neurosurgical assessment of resection completeness, radiation oncology input, neuro-oncology treatment planning, and a multidisciplinary tumor board discussion. A single institution or remote review program coordinates all of this.
Why a second opinion matters more in GBM than in most cancers
Glioblastoma is now classified under the WHO CNS5 (2021) framework primarily by molecular markers rather than by appearance alone. This means two tumor samples that look identical under a microscope can have different biology - each with a different predicted response to chemotherapy. A diagnosis made without full molecular profiling may be incomplete even if the microscopy is correct.
A National Brain Tumor Society guide on seeking a second opinion before brain surgery explains that a second specialist may interpret your diagnosis and treatment options differently after reviewing the same records. In neuro-oncology, that difference can affect which chemotherapy you receive, whether you qualify for a clinical trial, and whether additional molecular testing is worth doing before your first treatment.
If you are newly diagnosed and planning your first 30 days, the article on building your international expert review strategy in the first 30 days covers the timing and sequencing of this process in more detail.
Component 1: Independent neuropathology review
This is where any rigorous second opinion starts. A second neuropathologist from a different hospital reviews your tumor slides and tissue block without first reading the original pathologist's conclusions.
What the neuropathologist reviews:
- Hematoxylin and eosin (H&E) stained slides, which show the tumor structure and cell pattern
- Immunohistochemistry (IHC) panels for proteins such as GFAP (shows the tumor is a glial cell tumor), Ki-67 (shows how fast cells are dividing), and p53
- Confirmation that the tumor is WHO grade 4 and has features like necrosis and microvascular proliferation
- Assessment of tumor margins and tissue sample quality
For this review, the second-opinion center typically needs either the original glass slides or a high-resolution digital scan of them, plus the formalin-fixed paraffin-embedded (FFPE) tissue block. The FFPE block also provides the DNA needed for molecular testing.
The article on why independent pathology review matters before starting treatment covers cases where a second neuropathologist revised the initial diagnosis after examining the same tissue - and explains why this happens more often than most patients expect.
Component 2: Molecular marker testing
Most patients don't know they need to ask about this - and it often changes the treatment plan.
The 2021 WHO Classification of CNS Tumors reorganized glioma diagnosis to focus on molecular markers. A tumor that looks like glioblastoma on an MRI may need a different diagnosis or different treatment once the molecular profile is known. Research confirms that MGMT promoter methylation, IDH mutation status, and EGFR amplification affect how your tumor will respond to treatment.
Key markers your second-opinion review should confirm or include:
- IDH mutation status (IDH1 and IDH2) - tells the difference between IDH-wildtype GBM (the most aggressive form) and IDH-mutant tumors, which have different biology and may respond to different treatment
- MGMT promoter methylation - predicts how well the tumor may respond to temozolomide chemotherapy; a methylated MGMT promoter means better response to alkylating chemotherapy
- TERT promoter mutation - a key feature of IDH-wildtype GBM when combined with other markers under WHO CNS5
- EGFR amplification and EGFRvIII variant - relevant to several clinical trials and experimental targeted therapy programs
- CDKN2A/B homozygous deletion - used in WHO CNS5 to make certain IDH-mutant astrocytomas grade 4 instead of a lower grade
- PTEN loss - linked to treatment resistance and is being studied as a precision therapy target
If your original pathology report doesn't include all of these markers, the second-opinion center will likely need your FFPE block to run additional tests. The article on why molecular testing should happen in the first six weeks after surgery explains what gets missed when this step is delayed or incomplete.
Component 3: Neuroradiology re-read
Your MRI scans should be reviewed by a neuroradiologist - a specialist who reads brain tumor MRIs every day, not a general radiologist who looks at many different body parts. This matters in GBM, where telling the difference between residual tumor, treatment effect, and early recurrence requires specialized training that routine radiology doesn't provide.
A National Cancer Institute article on neuroradiology expertise explains that a specialist's MRI reading can find features that a general reading might miss or misidentify - a difference that matters for treatment planning.
What the neuroradiologist assesses in a second opinion:
- Contrast-enhancing tumor volume and whether surgery removed all the visible tumor on post-operative MRI
- Non-enhancing infiltrative disease visible on FLAIR sequences, which routine radiology reports often downplay
- Whether changes are pseudoprogression versus true progression - a key distinction if you are already in treatment
- Advanced sequences such as perfusion MRI, MR spectroscopy, or diffusion tensor imaging (DTI), if your original imaging included these
For this review, provide all imaging in DICOM format - raw scan files, not printed films or PDF copies. Most hospitals can transfer DICOM files to a disc, USB drive, or via a secure digital link if you ask your care team.
Component 4: Neurosurgical review
Even if surgery is already done, a neurosurgical second opinion is worth requesting. The reviewing neurosurgeon checks whether you had maximal safe resection, whether re-resection at the time of recurrence might help, and whether specialized surgical techniques - such as fluorescence-guided surgery using 5-ALA dye, which helps surgeons see tumor cells that are invisible under normal light - were available but not used in your original procedure.
If surgery hasn't happened yet, a neurosurgical review is even more important. Extent of resection is one of the strongest factors affecting outcome in GBM. A second neurosurgeon may suggest surgical approaches the first one didn't propose - including awake craniotomy for tumors near speech or motor areas.
Component 5: Radiation oncology input
Standard radiation for GBM after surgery typically means 60 Gy over six weeks, combined with temozolomide - the Stupp protocol. But the right approach for you depends on your age, fitness level, tumor location, and MGMT methylation status.
A radiation oncology review in a second opinion should look at:
- Whether the standard six-week course fits your case, or whether a shorter hypofractionated course is better - especially for older patients or those in poor health
- The treatment volumes in the original radiation plan, and whether nearby brain structures are adequately protected
- Whether proton therapy or other advanced delivery approaches offer real clinical benefit for your tumor location and anatomy
Component 6: Neuro-oncology treatment planning
The neuro-oncologist guides your full treatment - from choosing the right chemotherapy to watching for disease changes between MRI scans. In a complete second opinion, the neuro-oncologist reviews your case with full knowledge of your molecular profile, surgical report, and radiation plan all together.
Questions a second neuro-oncologist may raise that the first center didn't:
- Is the proposed chemotherapy matched to your tumor's molecular markers?
- Do you qualify for Tumor Treating Fields (TTFields/Optune) along with standard chemotherapy - and has anyone discussed this option with you?
- Do you qualify for any active clinical trials that weren't offered at your original center?
- Are there off-label or repurposed drugs worth discussing based on your tumor's molecular profile?
The American Brain Tumor Association's top questions to ask after a brain tumor diagnosis specifically highlights clinical trial eligibility as something to bring up early - something a second neuro-oncologist can assess once your full molecular data is ready.
Component 7: Multidisciplinary tumor board discussion
A tumor board is a group meeting where neurosurgery, neuro-oncology, radiation oncology, neuropathology, and neuroradiology specialists review your case together and agree on a recommendation. This matters because each specialist sees only part of the picture. The pathologist who confirmed your diagnosis hasn't read your MRI. The radiation oncologist planning your treatment may not have seen your operative report.
Research published in a study on the neuro-oncology multidisciplinary tumor board found that treatment plans changed in over 40% of cases after board review, with the neuroradiologist's independent re-reading driving most of those changes. That fact alone makes the tumor board the most important single step in getting a second opinion.
When you contact a second-opinion center, ask specifically whether your case will be discussed by the full multidisciplinary tumor board - not just one physician. The National Brain Tumor Society's tumor board FAQ explains what to ask and how to confirm your case is actually being discussed as a team, not sent to a solo reviewer.
If you are outside the country where you were diagnosed and travel is difficult right now, you may want to have the pathology and MRI reviewed by the Art of Healing Cancer team, which does remote multidisciplinary review for international patients without requiring travel.
Your complete second-opinion records checklist
Use this list to gather everything before contacting a second-opinion center. Most remote review programs accept digital files sent via secure upload.
- Pathology report - the full written report from your biopsy or surgical resection, including all molecular testing already done
- Tissue block and glass slides - the FFPE paraffin block and H&E slides from your surgery; contact your hospital's pathology department to arrange transfer or digital scanning
- All MRI scans in DICOM format - before surgery, during surgery (if available), and after surgery; include all sequences (T1, T1 with contrast, T2, FLAIR, DWI)
- Operative report - the neurosurgeon's detailed written account of the procedure, including how much tumor was removed and any findings during surgery
- All radiology reports - written reports for every MRI and CT scan done since diagnosis
- Radiation treatment plan - if radiation has been planned or started, get the full plan including dose volumes and target structure maps
- Current medication list - including corticosteroids such as dexamethasone, antiepileptic drugs, supplements, and vitamins
- A written list of your questions - include specific questions about clinical trial eligibility, molecular markers not yet tested, and whether different surgical or radiation approaches should be considered for your case
For detailed guidance on organizing these records and what each specialist looks at first, the article on preparing your tumor intelligence review walks through each document category and how to format your records for fast expert intake.
The American Brain Tumor Association's guide to organizing medical records after a brain tumor diagnosis also offers practical steps for tracking down records across hospital departments - a process that often takes longer than families expect.
Remote versus in-person second opinions
You don't need to travel to get a meaningful second opinion. Many major neuro-oncology programs now offer remote review - where your digital scans, pathology slides, and reports are submitted online and reviewed by a specialist team before a video consultation. Dana-Farber Cancer Institute and other leading centers have set up remote diagnostic pathways for patients who cannot travel in person.
For patients in the GCC, Africa, South Asia, and other regions where travel to a major cancer center is expensive or difficult, a structured remote review program makes expert care accessible without the cost and disruption of international travel. What matters is that the review truly involves multiple specialists - not just one doctor reading a PDF summary of your reports.
If you want to start this process, you can upload your MRI and reports and request a remote review at Glioblastoma Center's patient journey page, where a clinical navigator can help you figure out the next step.
When to talk to your doctor
Talk to your care team before requesting tissue transfer. Your hospital's pathology department needs written authorization to send slides or blocks to another institution, and that can take a week or more to arrange. Raise your interest in a second opinion as early as possible - most physicians support this step, and many specialist centers have a defined process for remote review that your primary team can help set up.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.